SavedAdd your journal

Journals / Güncel Retina Dergisi / 2021 / Cilt: 5 - Sayı: 2

Stargardt and Fundus Flavimaculatus; Current and Developing Treatments

Stargardt ve Fundus Flavimaculatus; Güncel Tedavi ve Geliştirilmekte olan Tedaviler

Çağatay ÇAĞLAR
Pages
190–200
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, the treatments investigated for the Stargardt disease are explained.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Stargardt macular dystrophy is a hereditary retinal degeneration that lacks effective treatment options.
📊
Key Findings & Data:These include investigational visual cycle modulators, complement inhibitors, ABCA4 gene therapy, and subretinal transplantation of stem cell derived retina pigment epitel cells.
💡
Conclusion & Impact:In this review, the treatments investigated for the Stargardt disease are explained.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Stargardt macular dystrophy is a hereditary retinal degeneration that lacks effective treatment options. The pathophysiology of disease is still not fully understood. While there are currently no available treatments for Stargardt disease, there are many categories of therapeutics under investigation to fulfill this unmet need for treatment. These include investigational visual cycle modulators, complement inhibitors, ABCA4 gene therapy, and subretinal transplantation of stem cell derived retina pigment epitel cells. Further trials are warranted to assess efficacy and safety in humans. In this review, the treatments investigated for the Stargardt disease are explained.

Özet

Stargardt maküler distrofisi etkin bir tedavisi olmayan herediter bir retina dejenerasyonudur. Hastalığının patofizyolojisi halen tam olarak anlaşılamamıştır. Şu an mevcut bir tedavisi olmasa da, tedavideki ihtiyacı karşılamak için birçok kategoride araştırmalar devam etmektedir. Bunlar görsel siklus inhibitörleri, kompleman inhibitörleri, ABCA4 gen terapisi, retina pigment epitel kaynaklı kök hücrenin subretinal transplantasyonudur. İnsanlarda etkin ve güvenli olarak değerlendirilebilecek bir tedavi için daha ileri çalışmalara ihtiyaç vardır. Bu derlemede Stargardt hastalığı için araştırılan tedaviler anlatılmıştır.

🔖

Cite This Article

ÇAĞLAR, Ç. (2021). Stargardt and Fundus Flavimaculatus; Current and Developing Treatments. Güncel Retina Dergisi, Cilt: 5 - Sayı: 2, 190–200. https://ajindex.com/articles/218402

References (13)

  1. Michaelides M, Hunt DM, Moore AT. The genetics of inherited macular dystrophies. J Med Genet. 2003;40(9):641–650.
  2. Stone EM, Andorf JL, Whitmore SS, DeLuca AP, Giacalone JC, Streb LM, et al. Clinically focused molecular investigation of 1000 consecutive families with inherited retinal disease. Ophthalmology 2017;124(9):1314–1331.
  3. Allikmets R, Shroyer NF, Singh N, Lewis RA, Bernstein PS, Peiffer A, et al. Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. Science 1997;277(5333):1805–1807.
  4. Allikmets R, Singh N, Sun H, Shroyer NF, Hutchinson A, Chidambaram A, et al. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet. 1997;15(3):236–246.
  5. Yi J, Li S, Jia X, Xiao X, Wang P, Guo X, et al. Evaluation of the ELOVL4, PRPH2 and ABCA4 genes in patients with Stargardt macular degeneration. Mol Med Rep. 2012;6(5):1045–1049.
  6. Ng KP, Gugiu B, Renganathan K, Davies MW, Gu X, Crabb JS, et al. Retinal pigment epithelium lipofuscin proteomics. Mol Cell Proteomics. 2008;7(7):1397–1405.
  7. Zernant J, Xie YA, Ayuso C, Riveiro-Alvarez R, Lopez-Martinez MA, Simonelli F, et al. Analysis of the ABCA4 genomic locus in Stargardt disease. Hum Mol Genet. 2014;23(25):6797–6806.
  8. Tsybovsky Y, Molday RS, Palczewski K. The ATP-binding cassette transporter ABCA4: structural and functional properties and role in retinal disease. Adv Exp Med Biol. 2010;703:105–125. Menteş J. Stargardt Hastalığı ve Fundus Flavimaculatus. Turkiye Klinikleri J Ophthalmol-Özel sayı 2009;2(1):20-26.
  9. Sparrow JR, Gregory-Roberts E, Yamamoto K, Blonska A, Ghosh SK, Ueda K, et al. The bisretinoids of retinal pigment epithelium. Prog Retin Eye Res. 2012;31(2):121–135.
  10. Sparrow JR, Boulton M. RPE lipofuscin and its role in retinal pathobiology. Exp Eye Res. 2005;80(5):595–606.
  11. Hussain RM, Gregori NZ, Ciulla TA, Lam BL. Pharmacotherapy of retinal disease with visual cycle modulators. Expert Opin Pharmacother. 2018;19(5):471–481.
  12. Röck T, Schatz A, Naycheva L, Gosheva M, Pach J, Wilhelm B, et al. Effects of transcorneal electrical stimulation in patients with Stargardt’s disease. Ophthalmologe 2013;110(1):68–73. Kondrot EC. Improvement in vision parameters for participants treated with alternative therapies in a 3-day program. Altern Ther Health Med. 2015;21(6):22–35.
  13. Teussink MM, Lee MD, Smith RT, Van Huet RA, Klaver CC, Klevering BJ, et al. The effect of light deprivation in patients with Stargardt disease. Am J Ophthal